Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients

Antiviral Therapy

Volumn 11, Issue 5, 2006, Pages 601-608

  Maagaard, Anne ^a,b   Holberg Petersen, Mona ^a   Kollberg, Gittan ^c   Oldfors, Anders ^c   Sandvik, Leiv ^a,b   Brunn, Johan N ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CELL NUCLEUS DNA; CYTOCHROME C; DIDANOSINE; LAMIVUDINE; MITOCHONDRIAL DNA; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA CONTENT; FEMALE; GEL ELECTROPHORESIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOCHEMISTRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIPOATROPHY; LIPOHYPERTROPHY; MALE; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL MYOPATHY; MITOCHONDRIAL TOXICITY; MONONUCLEAR CELL; MUSCLE BIOPSY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

BIOLOGICAL MARKERS; BIOPSY; DNA, MITOCHONDRIAL; DRUG MONITORING; ELECTRON TRANSPORT COMPLEX IV; FEMALE; GENE DELETION; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33748103186     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Oldfors A, Tulinius M. Mitochondrial encephalomyopathies. J Neuropathol Exp Neurol 2003; 62:217-227.
2. Kollberg G, Jansson M, Pérez-Bercoff Å, et al. Low frequency of mtDNA point mutations in patients with PEO associated with POLG1 mutations. Eur J Hum Genet 2005; 13:463-469.
3. Luoma P, Melberg A, Rinne JO, et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 2004; 364:875-882.
4. Johnson AA, Ray AS, Hanes J, et al. Toxicity of antiretroviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276:40847-40857.
5. Martin AM, Hammond E, Nolan D, et al. Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors. Am J Hum Genet 2003; 72:549-560.
6. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337:508-510.
7. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12:1735-1744.
8. Chariot P, Drogou I, de Lacroix-Szmania I, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999; 30:156-160.
9. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990; 322:1098-1105.
10. Shikuma CM, Hu N, Milne C, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001; 15:1801-1809.
11. Zaera MG, Miró Ò, Pedrol E, et al. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS 2001; 15:1643-1651.
12. Mallon PW, Unemori P, Sedwell, R, et al. for the SAMA Investigators. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the abscence of depletion of mitochondrial DNA. J Infect Dis 2005; 191:1686-1696.
13. Miró Ò, López S, Martínez E, et al. Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis 2004; 39:710-716.
14. Casula M, Bosboom-Dobbelaer I, Smolders K, et al. Infection with HIV-1 induces a decrease in mtDNA. J Infect Dis 2005; 191:1468-1471.
15. Jacotot E, Ravagnan L, Loeffler M, et al. The HIV-1-viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med 2000; 191:33-46.
16. Raidel SM, Haase C, Jansen NR, et al. Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage. Am J Physiol Heart Circ Physiol 2002; 282:H1672-H1678.
17. Polo R, Martínez S, Madrigal P, Gonzalez-Munoz M. Factors associated with mitochondrial dysfunction in circulating peripheral blood lymphocytes from HIV-infected people. J Acquir Immune Defic Syndr 2001; 34:32-36.
18. Côté HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811-820.
19. McComsey G, Tan DT, Lederman M, Wilson E, Wong LJ. Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS 2002; 16:513-518.
20. Miura T, Goto M, Hosoya N, et al. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. J Med Virol 2003; 70:497-505.
21. Chiappini F, Teicher E, Saffroy R, et al. Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients. Lab Invest 2004; 84:908-914.
22. López S, Miró Ò, Martínez E, et al. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir Ther 2004; 9:47-55.
23. Montaner JS, Côté HC, Harris M, et al. Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA. Clin Infect Dis 2004; 38(Suppl 2):73-79.
24. Maagaard A, Holberg-Petersen M, Kvittingen EA, Sandvik L, Bruun JN. Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1 infected treatment-naive patients. HIV Med 2006; 7:53-58.
25. Bergersen BM, Sandvik L, Bruun JN. Body composition changes in 308 Norwegian HIV-positive patients. Scand J Infect Dis 2004; 36:186-191.
26. Andreasson H, Gyllensten U, Allen M. Real-time DNA quantification of nuclear and mitochondrial DNA in forensic analysis. Biotechniques 2002; 33:402-404.
27. McComsey GA, Paulsen DM, Lonergan, JT, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19:15-23.
28. Moslemi AR, Melberg A, Holme E, Oldfors A. Autosomal dominant progressive external ophtalmoplegia: distribution of multiple mitochondrial DNA deletions. Neurology 1999; 53:79-84.
29. Sciacco M, Bonilla E, Schon, EA, DiMauro S, Moraes CT. Distribution of wild-type and common deletion forms of mtDNA in normal and respiration-deficient muscle fibers from patients with mitochondrial myopathy. Hum Mol Genet 1994; 3:13-19.
30. Vittecoq D, Jardel C, Cyrille B, et al. Mitochondrial damage associated with long-term antiretroviral treatment: associated alteration or causal disorder? J Acquir Immune Defic Syndr 2002; 31:299-308.
31. Cherry CL, Gahan ME, McArthur JC, Lewin SR, Hoy JF, Wesselingh SL. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 2002; 30:271-277.
32. Christensen ER, Stegger M, Jensen-Fangel S, Laursen AL, Ostergaard L. Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study. Clin Infect Dis 2004; 39:1371-1379.
33. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17:1329-1338.
34. Pace CS, Martin AM, Hammond EL, Mamotte CD, Nolan DA, Mallal SA. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther 2003; 8:323-331.
35. Haugaard SB, Andersen O, Pedersen SB, et al. Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy. J Med Virol 2005; 77:29-30.
36. Miró Ò, Gómez M, Pedrol, E, Cardellach F, Nunes V, Casademont J. Respiratory chain dysfunction associated with multiple mitochondrial DNA deletions in antiretroviral therapy-related lipodystrophy. AIDS 2000; 14:1855-1857.